MED Quote, Financials, Valuation and Earnings

Eventiko has a net margin of 0.81% compared to Medifast's net margin of --. Medifast's return on equity of 3.6% beat Eventiko's return on equity of --.

Medifast has a consensus price target of --, signalling downside risk potential of -2.48%. On the other hand Eventiko has an analysts' consensus of -- which suggests that it could fall by --. Given that Medifast has higher upside potential than Eventiko, analysts believe Medifast is more attractive than Eventiko.

Medifast has a beta of 1.172, which suggesting that the stock is 17.18% more volatile than S&P 500. In comparison Eventiko has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Medifast has a quarterly dividend of $1.65 per share corresponding to a yield of 0%. Eventiko offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medifast pays 73.45% of its earnings as a dividend. Eventiko pays out -- of its earnings as a dividend. Medifast's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medifast quarterly revenues are $140.2M, which are larger than Eventiko quarterly revenues of --. Medifast's net income of $1.1M is higher than Eventiko's net income of -$2.9K. Notably, Medifast's price-to-earnings ratio is 27.74x while Eventiko's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medifast is 0.27x versus -- for Eventiko. Usually stocks with elevated PS ratios are considered overvalued.

Patrick Industries has a net margin of 0.81% compared to Medifast's net margin of 4.45%. Medifast's return on equity of 3.6% beat Patrick Industries's return on equity of 14.42%.

Medifast has a consensus price target of --, signalling downside risk potential of -2.48%. On the other hand Patrick Industries has an analysts' consensus of $103.80 which suggests that it could grow by 25.2%. Given that Patrick Industries has higher upside potential than Medifast, analysts believe Patrick Industries is more attractive than Medifast.

Medifast has a beta of 1.172, which suggesting that the stock is 17.18% more volatile than S&P 500. In comparison Patrick Industries has a beta of 1.627, suggesting its more volatile than the S&P 500 by 62.678%.

Medifast has a quarterly dividend of $1.65 per share corresponding to a yield of 0%. Patrick Industries offers a yield of 1.81% to investors and pays a quarterly dividend of $0.40 per share. Medifast pays 73.45% of its earnings as a dividend. Patrick Industries pays out 29.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Medifast quarterly revenues are $140.2M, which are smaller than Patrick Industries quarterly revenues of $919.4M. Medifast's net income of $1.1M is lower than Patrick Industries's net income of $40.9M. Notably, Medifast's price-to-earnings ratio is 27.74x while Patrick Industries's PE ratio is 17.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medifast is 0.27x versus 0.76x for Patrick Industries. Usually stocks with elevated PS ratios are considered overvalued.

Interactive Strength has a net margin of 0.81% compared to Medifast's net margin of -354.57%. Medifast's return on equity of 3.6% beat Interactive Strength's return on equity of --.

Medifast has a consensus price target of --, signalling downside risk potential of -2.48%. On the other hand Interactive Strength has an analysts' consensus of -- which suggests that it could grow by 205379.45%. Given that Interactive Strength has higher upside potential than Medifast, analysts believe Interactive Strength is more attractive than Medifast.

Medifast has a beta of 1.172, which suggesting that the stock is 17.18% more volatile than S&P 500. In comparison Interactive Strength has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Medifast has a quarterly dividend of $1.65 per share corresponding to a yield of 0%. Interactive Strength offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medifast pays 73.45% of its earnings as a dividend. Interactive Strength pays out -- of its earnings as a dividend. Medifast's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medifast quarterly revenues are $140.2M, which are larger than Interactive Strength quarterly revenues of $2M. Medifast's net income of $1.1M is higher than Interactive Strength's net income of -$7.1M. Notably, Medifast's price-to-earnings ratio is 27.74x while Interactive Strength's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medifast is 0.27x versus 0.01x for Interactive Strength. Usually stocks with elevated PS ratios are considered overvalued.

WW International has a net margin of 0.81% compared to Medifast's net margin of -23.95%. Medifast's return on equity of 3.6% beat WW International's return on equity of --.

Medifast has a consensus price target of --, signalling downside risk potential of -2.48%. On the other hand WW International has an analysts' consensus of -- which suggests that it could fall by -18.88%. Given that WW International has more downside risk than Medifast, analysts believe Medifast is more attractive than WW International.

Medifast has a beta of 1.172, which suggesting that the stock is 17.18% more volatile than S&P 500. In comparison WW International has a beta of 1.726, suggesting its more volatile than the S&P 500 by 72.612%.

Medifast has a quarterly dividend of $1.65 per share corresponding to a yield of 0%. WW International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medifast pays 73.45% of its earnings as a dividend. WW International pays out -- of its earnings as a dividend. Medifast's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medifast quarterly revenues are $140.2M, which are smaller than WW International quarterly revenues of $192.9M. Medifast's net income of $1.1M is higher than WW International's net income of -$46.2M. Notably, Medifast's price-to-earnings ratio is 27.74x while WW International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medifast is 0.27x versus 0.13x for WW International. Usually stocks with elevated PS ratios are considered overvalued.